Key result
Adiponectin contributes to protection against cardiac remodelling and ischaemia-reperfusion injury, emerging as a potential cardioprotective agent for pathological heart conditions.
Adiponectin emerges as a potential cardioprotective target for treating pathological heart conditions due to its beneficial effects on cardiac remodelling and ischaemia-reperfusion injury.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for adiponectin as cardioprotective target; prospective trials required before clinical consideration.
Adiponectin is an adipose tissue-derived plasma protein which has a reduced concentration in subjects with obesity-related diseases. Adiponectin has antidiabetic and anti-inflammatory characteristics, which lead to beneficial actions on various obesity-linked complications. Recent experimental findings have shown that adiponectin contributes to protection against cardiac remodelling after pressure overload and cardiac injury following ischaemia-reperfusion. Thus, adiponectin could emerge as a potential cardioprotective agent for the treatment of several pathological heart conditions.
No takes yet. Share an insight, caveat, or question.
Ouchi et al. (2006) conducted a review in Obesity-related diseases and pathological heart conditions. Adiponectin was evaluated. Adiponectin contributes to protection against cardiac remodelling and ischaemia-reperfusion injury, emerging as a potential cardioprotective agent for pathological heart conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: